This Nottingham-based company works with research organisations to develop drugs for illnesses such as cancer, respiratory disease and Alzheimer’s, and in October last year announced a collaboration with Malaysian company, Viramatix, to develop anti-influenza medicine. Simon Hirst, 52, started Sygnature in 2004. Customers in America, Germany, Denmark and Australia lifted overseas sales to £5.8m in 2016, when it also took a stake in Cheshire-based Peak Proteins.
|Activity||New drug researcher|
|2 yr av intl sales growth % pa||32.30%|
|International sales £000s||5,827|
|Total sales £000s||12,330|
* Supplied by company † Annualised figure